Bioreactors Market Report 2026

The bioreactors market size has grown rapidly in recent years. It will grow from $10.61 billion in 2025 to $12.2 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to expansion of biologics production, growth in fermentation-based manufacturing, rising adoption of fed-batch processes, increasing investment in biopharma R&D, availability of advanced bioprocess control systems.

The bioreactors market size is expected to see rapid growth in the next few years. It will grow to $21.03 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing demand for high-yield bioprocessing, expansion of personalized medicine manufacturing, rising integration of ai-driven process optimization, growing focus on production efficiency, increasing adoption of continuous manufacturing models. Major trends in the forecast period include increasing adoption of automated bioreactor systems, rising use of continuous bioprocessing technologies, growing demand for scalable bioreactor platforms, expansion of single-use bioreactor solutions, enhanced focus on process monitoring and control.

The rising demand for biopharmaceuticals is expected to drive the growth of the bioreactors market in the coming years. Biopharmaceuticals are medicinal products derived from biological sources, including proteins, cells, and living organisms, used to prevent, treat, or manage various diseases. The growing need for biopharmaceuticals is driven by advancements in medical research, personalized medicine, and the demand for innovative treatments, resulting in improved healthcare outcomes globally. Bioreactors play a critical role in biopharmaceutical production by enabling efficient and scalable manufacturing of therapeutic products, ensuring consistent quality, lowering production costs, and supporting the development of innovative and life-enhancing medicines. For example, in November 2025, the Organisation for Economic Co-operation and Development, a France-based intergovernmental economic organization, reported that per capita expenditure on retail pharmaceuticals averaged USD 766 (adjusted for purchasing power differences) in OECD countries in 2023. Consequently, the rising demand for biopharmaceuticals is fueling growth in the bioreactors market.

Key companies in the bioreactors market are concentrating on developing advanced products such as fixed-bed bioreactors to support the cultivation of more complex biological cultures. A fixed-bed bioreactor is a type of bioreactor where biological organisms attach to a solid support, typically made of porous materials like beads, fibers, or granules. This design improves mass transfer, reduces shear stress, and offers better control over biological processes. For instance, in October 2024, Univercells Technologies, a Belgium-based biotechnology company, launched the Scale-X Nexo bioreactor. This state-of-the-art bioreactor, featuring a 0.5 m² growth surface, is specifically designed to optimize cell culture process development, providing significant advantages for biopharmaceutical companies and research institutions. The Scale-X Nexo allows seamless scalability to larger models, decreases media and reagent consumption, and can reduce operational costs by up to 60% compared to conventional entry-level bioreactors. Additionally, it integrates with the Skaia Vision application software, enhancing productivity by delivering precise cell count estimations without the need for direct sampling.

In March 2025, Syngene International, a Biocon subsidiary and India-based contract research and manufacturing organization (CRDMO), acquired a U.S. biologics facility from Operations Baltimore, LLC, a unit of Emergent BioSolutions, Inc. Through this acquisition, Syngene intends to expand its bioprocessing capacity, particularly its single-use bioreactor infrastructure, to accommodate more biologics and volume-intensive clients. Emergent BioSolutions, a U.S.-based biopharmaceutical company, previously operated the acquired facility with bioreactors for large-scale biologics production.

Major companies operating in the bioreactors market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Cytiva Bioscience Holding Ltd., Sartorius AG, Cellexus Ltd., Getinge AB, Eppendorf AG, ZETA Holding, Pierre Guerin, PBS Biotech Inc., TAP Biosystems, BBI-Biotech GmbH, HiTec Zang GmbH, Bioengineering AG, Infors AG, Univercells Technologies SA, CerCell A/S, Bailun Biotechnology Co. Ltd., BioNet, Shanghai Ritai Medicine Equipment Project Co. Ltd.

North America was the largest region in the bioreactors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioreactors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bioreactors market by increasing costs of imported stainless steel vessels, control systems, sensors, agitation components, and automation hardware used in laboratory and production-scale bioreactors. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported equipment, while Asia-Pacific faces cost pressure on bioreactor exports. These tariffs are increasing capital investment requirements and extending procurement timelines. However, they are also supporting domestic equipment manufacturing, regional supplier development, and innovation in cost-optimized bioreactor system design.

The bioreactors market research report is one of a series of new reports that provides bioreactors market statistics, including bioreactors industry global market size, regional shares, competitors with a bioreactors market share, detailed bioreactors market segments, market trends and opportunities, and any further data you may need to thrive in the bioreactors industry. This bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A bioreactor is a controlled system engineered to support biological processes by creating a suitable environment for cells, microorganisms, or enzymes to grow and perform their functions. It regulates optimal conditions such as temperature, pH, oxygen, and nutrient supply to enable specific biochemical reactions. Bioreactors find extensive applications in pharmaceuticals, food production, and wastewater treatment.

The primary types of bioprocesses for bioreactors include batch, fed-batch, and continuous. Bioreactors accommodate both batch and fed-batch processes, offering flexibility to optimize production according to product complexity and targeted yields. They are applicable to various cells, including mammalian, bacterial, yeast, and others, with multiple control options, such as manual and automated systems. Bioreactors are utilized for lab-scale, pilot-scale, and full-scale production and serve a range of end users, including research and development (R&D) organizations, biopharmaceutical manufacturers, and contract manufacturing organizations (CMOs).

The bioreactors market consists of sales of stirred-tank bioreactors (STRs), airlift bioreactors, bubble column bioreactors, and packed-bed bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.